Literature DB >> 33898558

Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.

Shuo Wang1, Huasheng Shi1, Tao Liu1,2, Manjiang Li1, Sanshun Zhou1, Xuan Qiu1, Zusen Wang3, Weiyu Hu3, Weidong Guo3, Xiaoqian Chen4, Honglin Guo4, Xiaoliang Shi4, Junping Shi4, Yunjin Zang1, Jingyu Cao3, Liqun Wu1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer worldwide. Although many studies have focused on oncogene characteristics, the genomic landscape of Chinese HCC patients has not been fully clarified.
METHODS: A total of 165 HCC patients, including 146 males and 19 females, were enrolled. The median age was 55 years (range, 27-78 years). Corresponding clinical and pathological information was collected for further analysis. A total of 168 tumor tissues from these patients were selected for next-generation sequencing (NGS)-based 450 panel gene sequencing. Genomic alterations including single nucleotide variations (SNV), short and long insertions and deletions (InDels), copy number variations, and gene rearrangements were analyzed. Tumor mutational burden (TMB) was measured by an algorithm developed in-house. The top quartile of HCC was classified as TMB high.
RESULTS: A total of 1,004 genomic alterations were detected from 258 genes in 168 HCC tissues. TMB values were identified in 160 HCC specimens, with a median TMB of 5.4 Muts/Mb (range, 0-28.4 Muts/Mb) and a 75% TMB of 7.7 Muts/Mb. The most commonly mutated genes were TP53, TERT, CTNNB1, AXIN1, RB1, TSC2, CCND1, ARID1A, and FGF19. SNV was the most common mutation type and C:G>T:A and guanine transformation were the most common SNVs. Compared to wild-type patients, the proportion of Edmondson grade III-IV and microvascular invasion was significantly higher in TP53 mutated patients (P<0.05). The proportion of tumors invading the hepatic capsule was significantly higher in TERT mutated patients (P<0.05). The proportion of Edmondson grade I-II, alpha fetoprotein (AFP) <25 µmg/L, and those without a history of hepatitis B was significantly higher in CTNNB1 mutated patients (P<0.05). CTNNB1 mutations were associated with TMB high in HCC patients (P<0.05). Based on correlation analysis, the mutation of TP53 was independently correlated with microvascular invasion (P=0.002, OR =3.096) and Edmondson grade III-IV (P=0.008, OR =2.613). The mutation of TERT was independently correlated with tumor invasion of the liver capsule (P=0.001, OR =3.030), and the mutation of CTNNB1 was independently correlated with AFP (<25 µmg/L) (P=0.009, OR =3.414).
CONCLUSIONS: The most frequently mutated genes of HCC patients in China were TP53, TERT, and CTNNB1, which mainly lead to the occurrence and development of HCC by regulating the P53 pathway, Wnt pathway, and telomere repair pathway. There were more patients with microvascular invasion and Edmondson III-IV grade in TP53 mutated patients and more patients with hepatic capsule invasion in TERT mutated patients, while in CTNNB1 mutated patients, there were more patients with Edmondson I-II grade, AFP <25 µmg/L, and a non-hepatitis B background. Also, the TMB values were significantly higher in CTNNB1 mutated patients than in wild type patients. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); gene mutation; next-generation sequencing (NGS); pathological features

Year:  2021        PMID: 33898558      PMCID: PMC8050591          DOI: 10.21037/hbsn.2019.09.17

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   8.265


  29 in total

1.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Authors:  Julien Calderaro; Gabrielle Couchy; Sandrine Imbeaud; Giuliana Amaddeo; Eric Letouzé; Jean-Frédéric Blanc; Christophe Laurent; Yacine Hajji; Daniel Azoulay; Paulette Bioulac-Sage; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2017-05-19       Impact factor: 25.083

2.  Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.

Authors:  Claire Goumard; Christele Desbois-Mouthon; Dominique Wendum; Claire Calmel; Fatiha Merabtene; Olivier Scatton; Françoise Praz
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

3.  Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.

Authors:  Sung-Min Ahn; Se Jin Jang; Ju Hyun Shim; Deokhoon Kim; Seung-Mo Hong; Chang Ohk Sung; Daehyun Baek; Farhan Haq; Adnan Ahmad Ansari; Sun Young Lee; Sung-Min Chun; Seongmin Choi; Hyun-Jeung Choi; Jongkyu Kim; Sukjun Kim; Shin Hwang; Young-Joo Lee; Jong-Eun Lee; Wang-Rim Jung; Hye Yoon Jang; Eunho Yang; Wing-Kin Sung; Nikki P Lee; Mao Mao; Charles Lee; Jessica Zucman-Rossi; Eunsil Yu; Han Chu Lee; Gu Kong
Journal:  Hepatology       Date:  2014-09-22       Impact factor: 17.425

4.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Authors:  Douglas B Johnson; Garrett M Frampton; Matthew J Rioth; Erik Yusko; Yaomin Xu; Xingyi Guo; Riley C Ennis; David Fabrizio; Zachary R Chalmers; Joel Greenbowe; Siraj M Ali; Sohail Balasubramanian; James X Sun; Yuting He; Dennie T Frederick; Igor Puzanov; Justin M Balko; Justin M Cates; Jeffrey S Ross; Catherine Sanders; Harlan Robins; Yu Shyr; Vincent A Miller; Philip J Stephens; Ryan J Sullivan; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2016-09-26       Impact factor: 11.151

5.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

6.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

7.  Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Authors:  David A Fabrizio; Thomas J George; Richard F Dunne; Garrett Frampton; James Sun; Kyle Gowen; Mark Kennedy; Joel Greenbowe; Alexa B Schrock; Aram F Hezel; Jeffrey S Ross; Phillip J Stephens; Siraj M Ali; Vincent A Miller; Marwan Fakih; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2018-08

8.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Authors:  Jean Charles Nault; Maxime Mallet; Camilla Pilati; Julien Calderaro; Paulette Bioulac-Sage; Christophe Laurent; Alexis Laurent; Daniel Cherqui; Charles Balabaud; Jessica Zucman-Rossi; Jessica Zucman Rossi
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330

10.  Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.

Authors:  Giuliana Amaddeo; Qian Cao; Yannick Ladeiro; Sandrine Imbeaud; Jean-Charles Nault; Daphne Jaoui; Yann Gaston Mathe; Christophe Laurent; Alexis Laurent; Paulette Bioulac-Sage; Julien Calderaro; Jessica Zucman-Rossi
Journal:  Gut       Date:  2014-06-09       Impact factor: 23.059

View more
  6 in total

1.  Genomic alterations in hepatocellular carcinoma and their clinical application to genomic medicine.

Authors:  Taisuke Imamura; Yukiyasu Okamura
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

2.  Hepatocellular carcinoma mutation landscape and its differences between Asians and Whites.

Authors:  Xingte Chen; Qiao Ke; Lei Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration.

Authors:  Dechao Cai; Xiao Ma; Huihui Guo; Haotian Zhang; Ashuai Bian; Haoran Yu; Wendan Cheng
Journal:  J Orthop Surg Res       Date:  2022-06-10       Impact factor: 2.677

4.  Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.

Authors:  Yongxiang Xia; Weiwei Tang; Xiaofeng Qian; Xiangcheng Li; Feng Cheng; Ke Wang; Feng Zhang; Chuanyong Zhang; Donghua Li; Jinhua Song; Hui Zhang; Jie Zhao; Aihua Yao; Xiaofeng Wu; Chen Wu; Guwei Ji; Xisheng Liu; Feipeng Zhu; Lang Qin; Xuan Xiao; Zhenhua Deng; Xiangyi Kong; Si Li; Yangyang Yu; Wenjing Xi; Wanglong Deng; Chuang Qi; Hanyuan Liu; Liyong Pu; Ping Wang; Xuehao Wang
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

5.  Oncogenic β-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer.

Authors:  Fangming Liu; Xiaochen Gai; Yuting Wu; Baohui Zhang; Xiaoyu Wu; Rongrong Cheng; Bufu Tang; Kezhuo Shang; Na Zhao; Weiwei Deng; Jie Chen; Zhengyi Zhang; Song Gu; Liang Zheng; Hongbing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-19       Impact factor: 12.779

Review 6.  Advances in postoperative adjuvant therapy for primary liver cancer.

Authors:  Zhi-Ming Zeng; Ning Mo; Jie Zeng; Fu-Chao Ma; Yan-Feng Jiang; Hua-Sheng Huang; Xi-Wen Liao; Guang-Zhi Zhu; Jie Ma; Tao Peng
Journal:  World J Gastrointest Oncol       Date:  2022-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.